# Systemic Lupus Erythematosus Research

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/systemic-lupus-erythematosus-research/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS), covering topics such as classification criteria, autoantibody development, interferon-inducible genes, nephritis, B lymphocyte depletion therapy, thrombosis risk, immunopathogenesis, toll-like receptors, and the epidemiology of autoimmune diseases. The research aims to improve understanding, diagnosis, classification, and management of SLE and APS. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t10308 |
| Works | 1,032 |

## Topic papers all

Showing 15 of 1032.

- [Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus](https://scholariq.org/papers/derivation-and-validation-of-the-systemic-lupus-international-collaborating/)
- [International consensus diagnostic criteria for neuromyelitis optica spectrum disorders](https://scholariq.org/papers/international-consensus-diagnostic-criteria-for-neuromyelitis-optica-spectrum/)
- [Derivation of the sledai. A disease activity index for lupus patients](https://scholariq.org/papers/derivation-of-the-sledai-a-disease-activity-index-for-lupus-patients/)
- [HOW CELLS RESPOND TO INTERFERONS](https://scholariq.org/papers/how-cells-respond-to-interferons/)
- [Nomenclature of Systemic Vasculitides](https://scholariq.org/papers/nomenclature-of-systemic-vasculitides/)
- [Evolving concepts of rheumatoid arthritis](https://scholariq.org/papers/evolving-concepts-of-rheumatoid-arthritis/)
- [Rheumatoid arthritis](https://scholariq.org/papers/rheumatoid-arthritis/)
- [SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX](https://scholariq.org/papers/systemic-lupus-erythematosus-disease-activity-index/)
- [Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations](https://scholariq.org/papers/association-analyses-identify-38-susceptibility-loci-for-inflammatory-bowel/)
- [EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update](https://scholariq.org/papers/eular-recommendations-for-the-management-of-rheumatoid-arthritis-with-synthetic-2/)
- [International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International workshop](https://scholariq.org/papers/international-consensus-statement-on-preliminary-classification-criteria-for/)
- [Development of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus](https://scholariq.org/papers/development-of-autoantibodies-before-the-clinical-onset-of-systemic-lupus/)
- [The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosus](https://scholariq.org/papers/the-development-and-initial-validation-of-the-systemic-lupus-international/)
- [2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus](https://scholariq.org/papers/2019-european-league-against-rheumatism-american-college-of-rheumatology/)
- [Rheumatoid arthritis](https://scholariq.org/papers/rheumatoid-arthritis-2/)

## Topic primary papers

Showing 15 of 687.

- [Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus](https://scholariq.org/papers/derivation-and-validation-of-the-systemic-lupus-international-collaborating/)
- [Derivation of the sledai. A disease activity index for lupus patients](https://scholariq.org/papers/derivation-of-the-sledai-a-disease-activity-index-for-lupus-patients/)
- [SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX](https://scholariq.org/papers/systemic-lupus-erythematosus-disease-activity-index/)
- [International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International workshop](https://scholariq.org/papers/international-consensus-statement-on-preliminary-classification-criteria-for/)
- [Development of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus](https://scholariq.org/papers/development-of-autoantibodies-before-the-clinical-onset-of-systemic-lupus/)
- [The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosus](https://scholariq.org/papers/the-development-and-initial-validation-of-the-systemic-lupus-international/)
- [2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus](https://scholariq.org/papers/2019-european-league-against-rheumatism-american-college-of-rheumatology/)
- [Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus](https://scholariq.org/papers/interferon-inducible-gene-expression-signature-in-peripheral-blood-cells-of/)
- [Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19](https://scholariq.org/papers/coagulopathy-and-antiphospholipid-antibodies-in-patients-with-covid-19/)
- [Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients](https://scholariq.org/papers/antiphospholipid-syndrome-clinical-and-immunologic-manifestations-and-patterns/)
- [Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/efficacy-and-safety-of-belimumab-in-patients-with-active-systemic-lupus/)
- [2019 update of the EULAR recommendations for the management of systemic lupus erythematosus](https://scholariq.org/papers/2019-update-of-the-eular-recommendations-for-the-management-of-systemic-lupus/)
- [The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited](https://scholariq.org/papers/the-classification-of-glomerulonephritis-in-systemic-lupus-erythematosus/)
- [A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus](https://scholariq.org/papers/a-phase-iii-randomized-placebo-controlled-study-of-belimumab-a-monoclonal/)
- [The classification of glomerulonephritis in systemic lupus erythematosus revisited](https://scholariq.org/papers/the-classification-of-glomerulonephritis-in-systemic-lupus-erythematosus-2/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.